$ALDX
Aldeyra Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022007890 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.249M $3.100M
YoY Change 37.08% 3.33%
% of Gross Profit
Research & Development $12.23M $7.726M
YoY Change 58.35% 16.54%
% of Gross Profit
Depreciation & Amortization $62.74K $67.86K
YoY Change -7.55% -3.05%
% of Gross Profit
Operating Expenses $12.23M $7.726M
YoY Change 58.35% -19.85%
Operating Profit -$16.48M -$10.83M
YoY Change 52.19% 12.37%
Interest Expense $406.0K $482.6K
YoY Change -15.88% 9.72%
% of Operating Profit
Other Income/Expense, Net -$304.6K -$458.8K
YoY Change -33.62% 99.73%
Pretax Income -$16.79M -$11.29M
YoY Change 48.7% 14.41%
Income Tax
% Of Pretax Income
Net Earnings -$16.79M -$11.29M
YoY Change 48.7% 14.41%
Net Earnings / Revenue
Basic Earnings Per Share -$0.29
Diluted Earnings Per Share -$288.0K -$247.4K
COMMON SHARES
Basic Shares Outstanding 58.10M
Diluted Shares Outstanding 58.30M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $216.9M $138.4M
YoY Change 56.65% 125.48%
Cash & Equivalents $158.9M $138.4M
Short-Term Investments $57.96M $0.00
Other Short-Term Assets $5.489M $8.600M
YoY Change -36.18% 514.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $222.4M $147.1M
YoY Change 51.19% 134.19%
LONG-TERM ASSETS
Property, Plant & Equipment $41.42K $57.56K
YoY Change -28.04% -80.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $337.9K $233.2K
YoY Change 44.92% 16.59%
TOTAL ASSETS
Total Short-Term Assets $222.4M $147.1M
Total Long-Term Assets $337.9K $233.2K
Total Assets $222.7M $147.3M
YoY Change 51.18% 133.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.443M $448.6K
YoY Change 444.56% -59.22%
Accrued Expenses $13.68M $5.372M
YoY Change 154.59% 41.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $5.100M
YoY Change -100.0%
Total Short-Term Liabilities $16.35M $11.10M
YoY Change 47.34% 126.53%
LONG-TERM LIABILITIES
Long-Term Debt $15.59M $10.14M
YoY Change 53.7% -31.01%
Other Long-Term Liabilities $63.33K
YoY Change
Total Long-Term Liabilities $15.59M $10.14M
YoY Change 53.7% -31.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.35M $11.10M
Total Long-Term Liabilities $15.59M $10.14M
Total Liabilities $32.00M $21.20M
YoY Change 50.96% 8.16%
SHAREHOLDERS EQUITY
Retained Earnings -$311.5M -$248.2M
YoY Change 25.49%
Common Stock $502.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $190.7M $126.1M
YoY Change
Total Liabilities & Shareholders Equity $222.7M $147.3M
YoY Change 51.18% 133.82%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$16.79M -$11.29M
YoY Change 48.7% 14.41%
Depreciation, Depletion And Amortization $62.74K $67.86K
YoY Change -7.55% -3.05%
Cash From Operating Activities -$12.87M -$13.47M
YoY Change -4.44% -12.29%
INVESTING ACTIVITIES
Capital Expenditures $16.32K $7.806K
YoY Change 109.03%
Acquisitions
YoY Change
Other Investing Activities -$58.02M
YoY Change
Cash From Investing Activities -$58.03M -$7.806K
YoY Change 743325.39% -100.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $70.05M
YoY Change -100.0% 2107.8%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 23.32K 74.06M
YoY Change -99.97% 2176.79%
NET CHANGE
Cash From Operating Activities -12.87M -13.47M
Cash From Investing Activities -58.03M -7.806K
Cash From Financing Activities 23.32K 74.06M
Net Change In Cash -70.88M 60.58M
YoY Change -217.0% -1129.84%
FREE CASH FLOW
Cash From Operating Activities -$12.87M -$13.47M
Capital Expenditures $16.32K $7.806K
Free Cash Flow -$12.89M -$13.48M
YoY Change -4.38% -12.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001341235
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-36332
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1968197
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
131 Hartwell Avenue
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 320
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
CY2022Q1 dei City Area Code
CityAreaCode
781
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
761-4904
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
ALDX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 us-gaap Assets
Assets
222692981
CY2021Q4 us-gaap Assets
Assets
233137120
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
63325
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2442830
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1019702
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13675555
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10523353
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
236048
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
229607
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16354433
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11772662
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58301491
CY2022Q1 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
93909328
CY2021Q4 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
104790989
CY2022Q1 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
65000000
CY2021Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
125000000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
57957020
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5488707
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2961781
CY2022Q1 us-gaap Assets Current
AssetsCurrent
222355055
CY2021Q4 us-gaap Assets Current
AssetsCurrent
232752770
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
296504
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
351863
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41422
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32487
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
125232
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15586501
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15503703
CY2022Q1 us-gaap Liabilities
Liabilities
32004259
CY2021Q4 us-gaap Liabilities
Liabilities
27401597
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58301491
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58301491
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58081215
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58081215
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
58301
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
58081
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
502172392
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
500369444
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-61677
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-311480294
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-294692002
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
190688722
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
205735523
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
222692981
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
233137120
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12234320
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7726342
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4249387
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3104702
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16483707
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10831044
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
101382
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
23762
CY2022Q1 us-gaap Interest Expense
InterestExpense
405967
CY2021Q1 us-gaap Interest Expense
InterestExpense
482580
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-304585
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-458818
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16788292
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-11289862
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58297861
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45630910
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16788292
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-11289862
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-61677
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-61677
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16849969
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11289862
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
205735523
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1779844
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
23324
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-61677
CY2022Q1 aldx Net Loss
NetLoss
-16788292
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
190688722
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
59508558
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1292170
CY2021Q1 aldx Issuance Of Common Stock Value In Connection With Acquisition Milestone
IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone
2499991
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
70049450
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4004290
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
9875
CY2021Q1 aldx Net Loss
NetLoss
-11289862
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
126074472
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-16788292
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-11289862
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1936578
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2381656
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
82798
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
141505
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3228
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
CY2022Q1 us-gaap Depreciation
Depreciation
62741
CY2021Q1 us-gaap Depreciation
Depreciation
67863
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2526926
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3429586
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1423128
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
66953
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2940002
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1410270
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12873199
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13471741
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16317
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7806
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
58015469
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58031786
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7806
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
70049450
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4004290
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
23324
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
9875
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23324
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74063615
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-70881661
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
60584068
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229790989
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77858311
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
158909328
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138442379
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
322500
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
341250
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1. NATURE OF BUSINESS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Aldeyra Therapeutics, Inc., together with its wholly-owned subsidiaries (the “Company” or “Aldeyra”), a Delaware corporation, is a clinical-stage biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients who suffer from immune-mediated diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company’s principal activities to date include business planning, research and development activities, and raising capital.</span>
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company’s management evaluates its estimates and assumptions on an ongoing basis. Management’s most significant estimates in the Company’s condensed consolidated financial statements include, but are not limited to, estimates related to clinical trial accruals, estimates related to deferred and accrued research and development costs, and accounting for income taxes and related valuation allowance. Although these estimates and assumptions are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span>
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6679372
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4428690
CY2022Q1 us-gaap Cash
Cash
87557084
CY2022Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
6352244
CY2022Q1 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
65000000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
158909328
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
58018697
CY2022Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
61677
CY2022Q1 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
57957020
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
158909328
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
57957020
CY2021Q4 us-gaap Cash
Cash
100364523
CY2021Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
4426466
CY2021Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
125000000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
229790989
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
229790989
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2022Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2022Q1 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
5056003
CY2021Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
2404145
CY2022Q1 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
11491712
CY2022Q1 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
432704
CY2021Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
557636
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5488707
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2961781
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1082096
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1512885
CY2021Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
8415560
CY2022Q1 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
1101747
CY2021Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
594908
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13675555
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10523353
CY2022Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2022Q1 aldx End Of Term Charge
EndOfTermCharge
755400
CY2021Q4 aldx End Of Term Charge
EndOfTermCharge
703269
CY2022Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
168899
CY2021Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
199566
CY2022Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2021Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15586501
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15503703
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
16042500
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
16042500
CY2022Q1 aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2019 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
CY2020 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
CY2022 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
CY2022Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
600000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1936578
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2381656
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4622870
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.73
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1350056
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.18
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5972926
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.16
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2199275
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3367053
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.98
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M26D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1515440
CY2022Q1 us-gaap Share Price
SharePrice
4.45
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
300000
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
63000.0
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
317934
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
18561
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
299373
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
236048
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
63325
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
299373
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
317934
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
189358
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
128576
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0

Files In Submission

Name View Source Status
0000950170-22-007890-index-headers.html Edgar Link pending
0000950170-22-007890-index.html Edgar Link pending
0000950170-22-007890.txt Edgar Link pending
0000950170-22-007890-xbrl.zip Edgar Link pending
aldx-20220331.htm Edgar Link pending
aldx-20220331.xsd Edgar Link pending
aldx-20220331_cal.xml Edgar Link unprocessable
aldx-20220331_def.xml Edgar Link unprocessable
aldx-20220331_htm.xml Edgar Link completed
aldx-20220331_lab.xml Edgar Link unprocessable
aldx-20220331_pre.xml Edgar Link unprocessable
aldx-ex31_1.htm Edgar Link pending
aldx-ex31_2.htm Edgar Link pending
aldx-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending